BioCentury | Nov 14, 2019
Company News

Via Allergan hair loss deal, Exicure builds balance sheet to advance oncology, neurology pipeline

...added that it complements Allergan's expertise in medical aesthetics and dermatology; the pharma markets Botox onabotulinumtoxinA...
BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

...The crown jewel in Allergan's portfolio is its $4.3 billion aesthetics franchise led by Botox onabotulinumtoxinA...
...drive growth.” He added that it’s “highly unlikely that we would see a biosimilar of Botox...
...McCallister, Senior Editor Botox Cosmetic (Brand), Botox (Brand), BTX-A (Compound #), botulinum toxin (Former generic), onabotulinumtoxinA (Generic), Botox...
BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

...SVP of neurosciences, urology and medical dermatology at Allergan plc (NYSE:AGN) and led the company's Botox...
BioCentury | Apr 11, 2019
Finance

Syncona eyes a matching pair

Ten months after rounding out its gene therapy strategy with the last two investments in a five-company portfolio, Syncona has decided that two of its companies will fare better as a single entity. Syncona Ltd....
BioCentury | Feb 1, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. OncoCyte said it will...
BioCentury | Jan 30, 2019
Company News

Allergan sheds $4.5B in market cap on 4Q18 earnings

...billion, partly due to loss of exclusivity, and below the Street’s $4.01 billion expectation. Botox onabotulinumtoxinA...
...by FactSet. Meghan Sullivan Botox Cosmetic (Brand), Botox (Brand), BTX-A (Compound #), botulinum toxin (Former generic), onabotulinumtoxinA (Generic), Botox...
BioCentury | Jan 29, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said Tuesday its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. The news sent...
BioCentury | Jan 25, 2019
Clinical News

Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

Asterias Biotherapeutics Inc. (NYSE-A:AST) reported 12-month data from the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI) showing that 21 of 22 patients (95%) who received 10 or 20 million cells of...
BioCentury | Jan 18, 2019
Financial News

Juvenescence raises first tranche of $100M series B

Juvenescence Ltd. (Douglas, Isle of Man) raised $46 million on Jan. 16 in the first tranche of a $100 million series B round as it continues to mull an IPO late this year. Co-founder and...
BioCentury | Jan 16, 2019
Financial News

Juvenescence raises first tranche of $100M series B

Juvenescence Ltd. (Douglas, Isle of Man) raised $46 million in the first tranche of a $100 million series B round as it continues to mull an IPO late this year. Co-founder and COO Alexander Pickett...
Items per page:
1 - 10 of 275